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Transgenic mouse models have emerged as plausible alternatives to long-term bioassays for
carcinogenicity. Three transgenic lines evaluated to date have shown a clear capability to
discriminate between carcinogens and noncarcinogens, using long-term bioassay results as the
standard. The data also suggest that the transgenic lines will not fully duplicate long-term
bioassay results. It is proposed that these models do not respond to chemicals that have induced
highly restricted species or strain-specific tumor responses in mice or rats. Rather, the value of
the transgenic models is predicated on a preferential response to transspecies carcinogens (i.e.,
those positive in both rats and mice, often including tumors in the same tissues). Thus, although
results in transgenic models may not be completely concordant with long-term bioassays, the
data can be used effectively in chemical and drug safety assessments. Further, it is proposed that
validation of the models is readily achievable via ongoing studies. Validation of any alternative
model is best achieved by sufficient mechanistic understanding of the model to reasonably
predict the outcome of bioassays conducted in the models and use all available information on
the drug or chemical. This goal can now be met with the transgenic mouse lines. Environ
Health Perspect 106(Suppl 2):473-476 (1998). http.//ehpnet1.niehs.nih.gov/docs/1998/Suppl-2/
473476tennantlabstract.html
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Introduction
In the hierarchy of data used in the
identification of causes of human cancer,
clinical observation and epidemiologic
studies provide the most definitive sources.
However, because these methods are
intrinsically retrospective, the long-term
two-species rodent bioassay is the most
generally accepted standard for identifying
potential carcinogens or, conversely, recog-
nizing chemicals, drugs, or environmental
factors that probably do not represent a
potential human carcinogen. In this con-
text, the application of in vivo alternative
methods refers specifically to alternatives to
the conventional rodent bioassay.
We have learned a great deal about
issues of validation and evaluation of
alternatives through the search for in vitro
methods that can replace or complement
long-term rodent studies, principally in the
field of genetic toxicology. It is estimated
that over the past two decades at least 100
different assays have been developed and
proposed to serve as alternative systems. The
evaluation of these methods has been at
times controversial, or at best difficult, but
the efforts nonetheless serve as aguide to the
types of issues that must be resolved for
methods to be generally used in place of
2-year rodent bioassays. Substantial amounts
ofliterature were created on genetic toxicity
test methods and various aspects have been
reviewed elsewhere (1,2). One of the most
thorough and objective evaluations was
This paper was prepared as background for the 13th Meeting of the Scientific Group on Methodologies for the
Safety Evaluation of Chemicals (SGOMSEC): Alternative Testing Methodologies held 26-31 January 1997 in
Ispra. Italy. Manuscript received at EHP9 May 1997; accepted 3 September 1997.
Address correspondence to Dr. R.W. Tennant, Laboratory of Environmental Carcinogenesis and
Mutagenesis, National Institute of Environmental Health Sciences, P.O. Box 12233, MD B3-09, Research
Triangle Park, NC 27709. Telephone: (919) 541-4141. Fax: (919) 541-1460. E-mail: tennant@niehs.nih.gov
Abbreviations used: p53def, heterozygous p53 knockout mouse line; NIEHS, National Institute of
Environmental Health Sciences; tg.AC; zetaglobin promoted v-Ha-ras transgenic mouse line; U.S. NTP, U.S.
National Toxicology Program.
conducted by the National Institute of
Environmental Health Sciences (NIEHS)/
U.S. National Toxicology Program (U.S.
NTP) and ultimately involved the evalua-
tion of 114 chemicals in four in vitroassays
(3,4). Subsequently, additional informa-
tion has been provided for in vivo assays
such as induction of chromosome aberra-
tions or micronuclei (5). The objectivity of
the effort included the use of coded sam-
ples and, when possible, samples from the
same lot of chemical as were used in the
2-year bioassay. Chemicals were chosen for
which definitive 2-year bioassay results
existed and samples were tested under
code. The results of this extended evalua-
tion served to verify the hypothesis that a
significant portion of rodent carcinogens
probably act via nonmutagenic mecha-
nisms and that existing in vitro assays were
inadequate to detect such nongenotoxic
carcinogens. However, the results summa-
rized elsewhere also permitted an intertest
comparison of the four genotoxicity assays
that were used (3,4). An interesting aspect
ofthe consequences ofthis effort relates to
the mouse lymphoma (TK+'-) in vitro
mutation assay, which demonstrated a rela-
tively high level of false positive results.
That is, the mouse lymphoma assay
responded to a high proportion of rodent
noncarcinogens that were not detected by
the other systems. Despite these results, the
mouse lymphoma assay continues to be
utilized for drug and chemical safety evalu-
ation (6). One reason for this paradox
appears to be the general belief that the
mouse lymphoma assay detects not only
point mutational effects of chemicals but
also responds to agents that have some clas-
togenic potential (7). However, use ofthis
assay is continued with the knowledge that
a proportion ofagents that produce a posi-
tive response are unlikely to be carcino-
genic in 2-year bioassays. This example is
given to focus on what may be an impor-
tant aspect of the validation process. That
is, that the validation process cannot be
proscriptively objectified and that the use
or acceptance of any given alternative sys-
tem will depend principally on subjective
notions about the uses and limitations of
the assay system. What then constitutes an
appropriate validation of new, more com-
plex in vivo alternative assays? In the
remainder of this paper, results of the use
of transgenic mouse models as bioassays
will be presented and related to how such
systems are scientifically validated.
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Implications of Long-Term
Bioassay Results
The significant advances of the past two
decades in identifying specific genes that
play critical oncogene or suppressor gene
roles in the process of carcinogenesis have
revealed objective targets for the action of
chemicals or other potential carcinogenic
agents. In conventional long-term rodent
bioassays, mice and rats are exposed for a
significant portion oftheir lifespan to con-
centrations of chemicals and lengths of
exposure that ensures systemic exposure of
all tissues ofthe body, as they are adminis-
tered at minimally toxic doses for 2 years. It
has been generallyassumed that this method
provides the greatest opportunity for identi-
fying potential carcinogens because all of
the tissues ofthe animals are put at risk for
possible neoplastic effects. The bioassay
identifies any cancers that are induced in
comparison to both a concurrent control
and historical control data. The concurrent
control group plays an intrinsic part in the
evaluation process because rodent strains
develop specific spontaneous tumors over
their lifespan that become confounding fac-
tors when evaluating whether a chemical,
individual environmental exposure, or drug
has induced cancer. Although there are
many important genes that are highly con-
served between rodents and humans, there
are specific genetic differences that deter-
mine spontaneous tumors (8,9). Because
the pattern and tissue type ofspontaneous
tumors are characteristic of individual
inbred rodent strains, it is obvious that these
spontaneous tumors have a specific genetic
origin. However, relatively few of the spe-
cific genetic determinants of spontaneous
cancers in rodents have been defined. One
particular locus that plays a role in the
development ofhepatocarcinogenesis in the
B6C3F1 mouse is the hcs locus (8). Efforts
to link spontaneous and induced hepatocar-
cinogenesis in B6C3F1 mice to mutations in
the H-rasgene have failed to show any dear
pattern (10). However, since the hcs locus
has not been cloned, it is not possible to
determine the specific relationship that this
locus may have to other identified genes, or
whether this is a mutation or a polymor-
phism ofa gene that plays a role in the nor-
mal regulatory processes in hepatic cells. A
major implication of the existence ofgenes
that determine spontaneous cancers is that
long-term exposure to chemicals, rather
than indicating an intrinsic property ofthe
chemical to induce carcinogenic effects, may
alternatively only show that a chemical has
the capability to modulate the expression of
genes. If a specific gene is a determinant of
spontaneous tumorigenesis in the rodent,
then a chemical could also affect genes that
alter the expression of the spontaneous
tumor gene. In such a case it is likely that
the presumed carcinogenic response may
only represent a strain- or species-specific
effect that results from a specific pattern of
inheritance. Thus, in terms ofimplications
for human health assessment such chemicals
would be unlikelyto pose ahazard.
A second factor that may complicate
the interpretation ofthe rodent bioassays is
strain or species susceptibility genes, which
can also influence the response ofspecific
strains or species to chemical effects. For
example, genes that are derived from the
highly polymorphic superfamily genes
influence interactions with and metabolism
ofchemicals and drugs (e.g., P450s orvari-
ous cellular receptors) and may determine
strain-specific responses to chemicals. Such
strain-specific responses would predictably
show as single sex, species, and site of
tumor induction (9).
Evaluation ofTransgenic
Mouse Models as
Carcinogen Bioassays
With foreknowledge of the existence of
genetic determinants ofspontaneous tumors
or strain-speciflc carcinogenicity in the
rodents used for the bioassay, it is possible
to continue to use the bioassay and provide
for discriminatory interpretation of results.
However, it is also possible that because
there have been important oncogenes or
tumor suppressor genes identified that play
critical roles in carcinogenic process, these
can be made the proximate targets for the
action of chemicals, thus bypassing the
potential for the influence of strain or
species-specific genes. We believe that this
goal has been met through the development
of transgenic mouse models in which spe-
cific genetic determinants have been either
inserted or deleted from the mouse genome,
rendering the animals specifically sensitive
to carcinogenic effects. The principal trans-
genic models currendy available and most
extensively utilized as bioassays are pre-
sented in Table 1. Although hundreds of
transgenic and knockout mouse lines have
been developed, most failed to demonstrate
phenotypic characteristics that would make
themgenerallyuseful in the taskofchemical
anddrugsafetyassessmentforcarcinogens.
The three transgenic models presented in
Table 1 each possess a phenotype that per-
mits selective responses to carcinogens
(15,16).Thoughthetotal numberofchemi-
cals tested thus far in each line islimited, the
data are sufficient to dearly indicate ways in
which the models could be used as carcino-
gen bioassays. The specific chemicals tested
to date in each model are provided in the
references cited in Table 1 and will not be
retabulated here. Each model has shown the
capability to respond in a specific manner to
exposure to carcinogens. Tumors have been
inducedwithin 6-month exposure periods at
doses that are the same or comparable to
those utilized in 2-year bioassays. With the
heterozygous p53 knockout mouse line
(p53def), the responses were in some cases at
the same site and ofthe same histogenic type
as those induced in animals in the 2-year
bioassay. In the p53ief model only ionizing
radiation (17) andthosechemicals ofknown
mutagenic potential (16) induced tumors.
The animals failed to respond to comparable
exposures to two nonmutagenic carcinogens.
These observations support the inference
that the p53d'f line can be used to derive
mechanistic insights about the carcinogenic
potential ofchemicals.
The zetaglobin promoted v-Ha-ras
transgenic mouse line (Tg.AC) possesses a
unique phenotype that is the product of
two primary properties that include the
activation ofthe mutated rasgene via afetal
globin promoter and the site ofintegration
(13). The induction ofskin papillomas by
topical exposure to tumor promoters and
carcinogens appears directly related to func-
tional properties ofthe zetaglobin promoter
and the location ofthe site ofintegration in
a domain that permits the transgene to be
expressed in the epidermis. The model is
consistent with the role of the mutated
endogenous Ha-ras gene in skin tumor
induction in the conventional two-stage
initiation-promotion process in mice (18).
That is, mutation of the endogenous
Table 1.Transgenic mouse lines available for use in carcinogenicity bioassays.
Transgenic line Genotype Phenotype Reference
p53def Knockoutofp53tumorsuppressorgene Heterozygous animals normal (11,12,16)
Tg.AC v-Ha-raswith zetaglobin promoter; Induced transgeneexpression in skin (13,14,16)
tandem insertion on chromosome 11 leadsto papilloma development
Tg-ras-H2/CB6F1 Human c-Ha-raswith endogenous Low background tumor incidence (15)
promoter
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Ha-ras gene is an initiating event in the
initiation-promotion protocol (19). How-
ever, in the TgAC model the induction of
papillomas appears to proceed via transcrip-
tional activation ofthe transgene. Transgene
expression has not been detectable in nor-
mal adult skin in the absence ofexposure to
carcinogens or development ofpapillomas
(20,21). Thus the mechanism ofthe model
is related to the capability of both muta-
genic and nonmutagenic carcinogens and
tumor promoters to activate expression of
the transgene. The expression ofthe trans-
gene appears to alter the terminal dif-
ferentiation pattern of basal keratinocytes,
resulting in agrowth imbalance thatleads to
the development ofthe papillomas. A high
proportion (approximately 40%) ofanimals
that develop a papilloma also develop squa-
mous cell carcinomas that likewise highly
express the transgene. A useful way ofview-
ing the model is to consider the induction
of papillomas as a reporter phenotype for
carcinogenic potential. Of the chemicals
tested to date for which 2-year bioassay data
are available, the model has shown a highly
specific response pattern and has yielded no
false positive results (16). In addition to
skin exposure, preliminary results with
dimethyl vinyl chloride administered via
gavage indicates that the forestomach
epithelium is also sensitive; the chemical
induced forestomach papillomas that
expressed the transgene. It is possible there-
fore that the oral route ofexposure may be
useful, but moredata areneeded.
The Tg-ras-H2 transgenic mouse line
was developed utilizing an endogenous
human c-Ha-ras gene with its endogenous
promoter sequence. Preliminary results
suggested that the model demonstrated an
increased sensitivity to chemically induced
carcinogenesis (15). Subsequent studies
increased the number of chemicals to
which the animal is sensitive; the study ofa
large group of chemicals is currently in
progress at the Japanese National Institute
ofEnvironmental Health Sciences (Tokyo)
and the Japanese Central Institute for
Experimental Animals (Kawasaki). This
model differs from both thep53defand the
Tg.AC lines in that the transgene is
endogenous protooncogenes. Studies are
currently underway to understand the
mechanism by which various carcinogens
induce tumors in this model.
Papers published to date providing
information on the chemicals that have
been tested in these transgenic models, and
details of their genotype and phenotypic
characteristics are listed in the bibliography
(11,13,14,16). It is also possible to obtain
the latest information available on the
studies in transgenic models conducted by
the NIEHS/U.S. NTP via the Internet
(22). This Internet site will be used to
solicit nominations for further studies in
transgenics, list chemicals currently being
studied, and provide summary results as
they become available.
Validation of
Transgenic Bioassays
The basic proposition of this paper is that
although the data are limited for the num-
ber ofchemicals that have been evaluated in
the three transgenic models, the results are
sufficient to allow incorporation of results
from these models into the safetyassessment
of chemicals and drugs. The safety assess-
ment, hazard identification, and risk evalua-
tion processes are intrinsicallysubjective and
bytheirvery nature must be done byweight
ofevidence. That is, all the available data on
the properties and biologic effects of the
chemical ordrug must be used in evaluating
human risk (1,2). There is no proscriptive
formula to effectively safeguard human
health and permit the valid utilization of
chemicals and drugs. Although the rodent
bioassay is viewed by some as the gold stan-
dard for safety assessment, it is actually one
tool with which to judge the biologic effects
of chemicals. It is obvious that rodents are
imperfect surrogates for the human popula-
tion. Results in the rodent can be validly
compared to those in humans for a variety
of substances, and though many genetic
determinants are highly conserved between
the species, there are manymore geneticdif-
ferences that significantly impact on judg-
ments ofhazard evaluation. As stated above,
the principal manifestations of these differ-
ences in regard to the bioassay are the high
background rates of spontaneous tumors
and evidence ofstrain-specific responses to
chemicals. These observations do not invali-
date the bioassay, as known human carcino-
gens are also carcinogenic in rodent models,
but conversely, it does not mean that every
effect observed in the rodent is necessarily
predictive ofhuman health hazard. We have
advocated that the transgenic models can
complement and eventually supplant the
use of the long-term rodent bioassays by
minimizing strain-specific responses without
significantly diminishing the capability to
recognize the transspecies carcinogens that
are likely the most proximate human health
hazard identified in the long-term bioassay.
Thosewho hold to a literal interpretation of
bioassay results, i.e., any effect in the rodent
is probably indicative of a human health
risk, will not endorse the use ofsuch models
because they are predicated on the principle
that theywill not respond to the majority of
chemicals that have shown highly strain- or
site-specific effects in the 2-yearbioassay.
The issue ofwhat constitutes an appro-
priate validation can be best addressed by
viewing experience with the long-term
bioassay. The bioassay as it is conducted
today has evolved for over two decades in
concept, methodology, and interpretation,
and some have asserted that the model has
never been appropriatelyvalidated. I believe
thatvalidation has been achievedviaexperi-
ence. We have come to recognize the
potential uses and limitations ofthe bioas-
say and scenarios have been developed to
address the various circumstances in which
the outcome ofbioassays maybe at variance
with anticipated results based on chemical
structure, toxicity, or other properties.
Mechanistic inference rarely can be used to
assess the results. Some notable exceptions
are the case of the a2-microglobulin-
induced tumors in male rat kidneys. The
most problematic interpretations involve
increases only in incidence of tumors that
have ahigh spontaneous rate.
Despite these interpretive uncertainties
it has been possible to demonstrate that a
high proportion of the outcomes of bioas-
says can be predicted based on utilizing
information on chemical structure, genotox-
icity, subchronic toxicity, etc. The least pre-
dictive certainty is associated with chemicals
that produced highly selective carcinogenic
effects (i.e., single-site or single-sex species
tumor induction) and for those that induce
equivocal responses. The highest degree of
predictive confidence is associated with the
chemicals that produced transspecies car-
cinogenic effects and that were genotoxic
and/or relatively highly toxic in subchronic
studies. Thus, although a formal validation
has never been conducted for the long-term
rodent studies, the capability to predict
bioassay results to a reasonable degree con-
firms the fact that there is understanding
and confidence in the use ofthis method for
chemical anddrugsafetyassessment.
A syllogism to justify the use of trans-
genic bioassays is that a) if the transgenic
bioassays can reproduce the predictable
responses ofthe long-term bioassay, and do
so with significant reduction in time and
cost, and b) ifthe transgenic bioassay result
likewise can be predicted based on similar
information relating to chemical structure,
genotoxicity, and systemic toxicity, then
c) the transgenic bioassays should provide a
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plausible and acceptable alternative to the
long-term studies. At the current stage of
development and understanding, the high-
est level ofpredictive confidence is associ-
ated with thep53def transgenic model. The
circumstantial evidence that associates
mutagenic potential with carcinogenic
potential is high (though not certain, as
approximately 30% of mutagens are not
tumorigenic in the long-term rodent bioas-
says). Because a high proportion ofhuman
tumors carry mutations in thep53gene it is
plausible to predict that mutagenic chemi-
cals may produce a positive response in the
p53defanimal via mutational inactivation or
loss of the functional p53 allele. This
hypothesis must be tested experimentally,
but the results obtained thus far provide
some confidence that the mechanistic basis
of the response of thep53def line is consis-
tent with the other data. Under these cir-
cumstances it is plausible at present to adapt
the use of the p53def line to verify the
carcinogenic potential ofmutagenic chemi-
cals; a positive response in this model should
form the basis for effective chemical safety
assessment. In addition, because group sizes
can be much smaller than in long-term
bioassays, it is plausible to conduct extensive
dose-range evaluation to determine whether
possible no effect levels exist for the action
of the chemical. Sample sizes required to
achieve high levels ofconfidence for very
low frequency events are still large, but the
absence of induced effects in sequential
doses ofchemicals in the transgenic model
can provide useful information about the
relative carcinogenic potential ofa chemical.
The absence of any induced tumors in a
transgenic bioassay with the p53def model
could indicate that despite its mutagenic
properties, the chemical is not intrinsically
carcinogenic, or it could mean that thep53
model is unresponsive in tissue sites at
which the chemical might demonstrate a
carcinogenic effect. At this stage of our
understanding, these two alternatives cannot
bediscriminated effectively, butas additional
experiencewith agreatervarietyofchemicals
or drugs is obtained, distinction between
these possibilities should beresolvable.
The Tg.AC transgenic model has shown
clear-cut responses to both mutagenic and
nonmutagenic chemicals administered topi-
cally. Apparently, induction ofpapillomas is
a direct consequence of the activation of
transgene expression in aspecific population
ofcells that appear to reside predominately
within the upperfollicular epithelium.
In summary, the available though lim-
ited data for chemical effects in transgenic
mouse models indicate that selected models
can play a role in drug and chemical safety
evaluation. The validation ofthe models is
an evolving process, but sufficient under-
standing of the mechanisms of tumor
induction in transgenic lines exists to make
plausible predictions for the outcome of
transgenic bioassays.
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